• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 6:24:53 AM ET
    $SNSS
    Major Pharmaceuticals
    Health Care
    Get the next $SNSS alert in real time by email
    SC 13G/A 1 tm216457d43_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    SUNESIS PHARMACEUTICALS, INC.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    867328874

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 8 Pages

     

     

     

     

     

     

    CUSIP NO.  867328874 Page 2 of 8 Pages

     

    CUSIP No.  867328874
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 0
    (7) Sole dispositive power 0
    (8) Shared dispositive power 0
    (9) Aggregate amount beneficially owned by each reporting person 0
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 0%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO.  867328874 Page 3 of 8 Pages

     

    CUSIP No.  867328874
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 0
    (7) Sole dispositive power 0
    (8) Shared dispositive power 0
    (9) Aggregate amount beneficially owned by each reporting person 0
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 0%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO.  867328874 Page 4 of 8 Pages

     

    CUSIP No.  867328874
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 0
    (7) Sole dispositive power 0
    (8) Shared dispositive power 0
    (9) Aggregate amount beneficially owned by each reporting person 0
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 0%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO.  867328874 Page 5 of 8 Pages

     

    Item 1(a). Name of Issuer:
       
     

    SUNESIS PHARMACEUTICALS, INC. (the “Issuer”).

       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
     

    395 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080

       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

       
    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.0001 par value (the “Shares”).

       
    Item 2(e). CUSIP Number:
     

     

    867328874

     

     

     

     

    CUSIP NO.  867328874 Page 6 of 8 Pages

     

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:  

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e)x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g)x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h)¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4. Ownership:
       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2020, Nantahala may be deemed to be the beneficial owner of 0 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2020, each of the Reporting Persons may be deemed to be the beneficial owner of 0% of the total number of Shares outstanding.

     

     

     

     

    CUSIP NO.  867328874 Page 7 of 8 Pages

     

    Item 4(c). Number of shares as to which such person has:
       
      Nantahala Capital Management, LLC  
       
      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote

    0

      (iii) Sole power to dispose or to direct the disposition of 0
            (iv) Shared power to dispose or to direct the disposition of

    0

     

      Each of Messrs. Harkey and Mack:  
       
      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote

    0

      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of

    0

           

    Item 5. Ownership of Five Percent or Less of a Class:
       
     

    The Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock.

       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E). See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
     
    Item 10. Certification:

     

     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP NO.  867328874 Page 8 of 8 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 16, 2021 NANTAHALA CAPITAL MANAGEMENT, LLC
       
      By: /s/ Paul E. Rehm
        Paul E. Rehm
        Chief Compliance Officer
       
       /s/ Wilmot B. Harkey
      Wilmot B. Harkey
       
      /s/ Daniel Mack
      Daniel Mack

     

     

     

    Get the next $SNSS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNSS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

      SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the trea

      2/16/21 8:00:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

      SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021 and the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. The Company will present and participate in one-on-one investor meetings at both conferences. Details on the events can be found below. LifeSci Partners Precision Oncology Day Date: Wednesday, February 17, 2021 Time: 2:30 PM ET Format: Corporate presentation 10th Annual SVB Leerink Globa

      2/11/21 4:05:00 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

      SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas. At the 62nd American Society of Hematology (ASH) Annual Meeting, Dr. Pierluigi Porcu of Sidney Kimmel Cancer Center, Thomas Jefferson University, presented updated data from Viracta's ongoing clinical trial evaluating its all-oral combination regimen of nanatinostat and valganciclovir for the treatment of patients with R/R EBV+ lymphoma that had failed one or more prior therapies

      12/7/20 8:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by J. Barry Simon

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:46:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by Stephen Rubino

      3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)

      3/4/21 5:42:13 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock

      3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)

      2/25/21 6:09:20 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Market Perform to Outperform and set a new price target of $12.00

      3/1/21 8:39:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Sunesis Pharmaceuticals from Perform to Outperform and set a new price target of $12.00

      2/23/21 5:59:10 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    SEC Filings

    See more
    • SEC Form 8-K filed

      8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)

      3/4/21 4:06:03 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 8-K filed

      8-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 4:34:51 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form 10-K filed

      10-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)

      2/24/21 6:06:16 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Financials

    Live finance-specific insights

    See more
    • Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

      Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have approximately $120 million cash balance following the close of the merger Companies to host conference call today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta

      11/30/20 7:30:00 AM ET
      $SNSS
      Major Pharmaceuticals
      Health Care

    $SNSS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed

      SC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/10/21 9:40:22 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/8/21 5:05:56 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)

      3/5/21 1:30:27 PM ET
      $SNSS
      Major Pharmaceuticals
      Health Care